will compound semaglutide be banned Compounded Banned? Facts & Safety What to know about the

Tirzepatide (Mounjaro) (Note: Technically a dual GLP-1/GIP agonist) Approved for diabetes, with weight loss benefits under clinical evaluation for obesity

However, little is known about the consequences of discontinuation on MACE risk

If you discover you are pregnant while taking Retatrutide, stop immediately and contact your healthcare provider

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with obesity

- TRIUMPH-3: Weight management trial in adults with established cardiovascular disease

For patients considering weight management options, understanding the pharmacological rationale, potential synergies, and safety profile of combination approaches is essential for informed conversations with healthcare providers